首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

Expert Review of Neurotherapeutics
ISSN：1473-7175

Expert Review of Neurotherapeutics

EXPERT REV NEUROTHER
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：-
新锐分区：医学3区
年发文量：91
影响因子：3.4
JCR分区：Q2

基本信息

神经治疗学专家评论（ISSN 1473-7175）提供了关于临床神经病学和神经精神病学中药物和药物使用的专家评论。覆盖范围包括疾病管理、新药物和神经病学药物、治疗适应症、诊断、医疗指南以及中风、癫痫、阿尔茨海默氏症和帕金森氏症等神经疾病。每项审查的全面覆盖范围由独特的专家审查格式补充，包括以下部分：专家意见--对文章中数据的个人观点，对未来可能重要的发展的讨论，以及随着进一步研究产生更详细的结果而可能变得令人兴奋的研究途径文章亮点--作者最关键观点的执行摘要
1473-7175SCIE/Scopus收录
3.4
点击查看最新影响趋势>
4.2
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
CLINICAL NEUROLOGY 临床神经病学
3区
PHARMACOLOGY & PHARMACY 药学
3区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：CLINICAL NEUROLOGY
SCIE
Q2
78/286
学科：PHARMACOLOGY & PHARMACY
SCIE
Q2
113/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：CLINICAL NEUROLOGY
SCIE
Q3
157/286
学科：PHARMACOLOGY & PHARMACY
SCIE
Q2
171/353
63
91
点击查看年发文量趋势图>
4%---CLINICAL NEUROLOGY-PHARMACOLOGY & PHARMACY
2.9%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
16.48%6.3%0.95%
CiteScore：6.40
SJR：1.162
SNIP：1.044
学科类别分区排名百分位
大类：Medicine
小类：Neurology (clinical)
Q1
91 / 400
大类：Medicine
小类：Pharmacology (medical)
Q1
63 / 275
大类：Medicine
小类：General Neuroscience
Q2
39 / 111

期刊高被引文献

Gut microbiota in ALS: possible role in pathogenesis?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1623026
Biomarkers for bipolar disorder: current status and challenges ahead
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1550361
Multidisciplinary care for people with Parkinson’s disease: the new kids on the block!
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1561285
Intracerebral hemorrhage: an update on diagnosis and treatment
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1623671
Fremanezumab as a preventive treatment for episodic and chronic migraine
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1614742
The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2020.1707668
Disease-modifying therapies for tauopathies: agents in the pipeline
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1606715
Stiripentol for the treatment of seizures associated with Dravet syndrome
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1593142
Evidence-based treatment of Tourette’s disorder and chronic tic disorders
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1643236
Contemporary management of the pseudotumor cerebri syndrome
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1660163
Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1635457
Traditional Ayurvedic and herbal remedies for Alzheimer’s disease: from bench to bedside
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1596803
Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1628640
Cortico-limbic connectivity as a possible biomarker for bipolar disorder: where are we now?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1562338
Therapeutic strategies for social anxiety disorder: where are we now?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1666713
Antihypertensive agents in Alzheimer’s disease: beyond vascular protection
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2020.1708195
Timing use of novel anti-epileptic drugs: is earlier better?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1636649
Emerging therapies in Huntington’s disease
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1631161
Glial cells as therapeutic targets in progressive multiple sclerosis
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1614443
The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1666712
Neuromodulation for the treatment of primary headache syndromes
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1585243
Paroxysmal movement disorders – practical update on diagnosis and management
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1648211
Taurine and GABA neurotransmitter receptors, a relationship with therapeutic potential?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1593827
An update on thymectomy in myasthenia gravis
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1600404
Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1617701
An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2020.1699060
Cariprazine for the treatment of bipolar depression: a review
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1580571
An update on EEG in migraine
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1586534
Extended-Release Amantadine for Levodopa-Induced Dyskinesia
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1592677
Imaging in the diagnosis of idiopathic inflammatory myopathies; indications and utility
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1572507
Cognitive remediation therapy of working memory in addictive disorders: An individualized, tailored, and recovery-oriented approach
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1591950
Parkinson’s disease management and impulse control disorders: current state and future perspectives
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1620603
Controversies in the management of neuromyelitis optica spectrum disorder
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1648210
Discriminating schizophrenia disease progression using a P50 sensory gating task with dense-array EEG, clinical assessments, and cognitive tests
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1601558
Sensory-targeted cognitive training for schizophrenia
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1581609
An update on neurocritical care for intracerebral hemorrhage
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1618709
Advantages and limitations of amino acid PET for tracking therapy response in glioma patients
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2020.1704256
Intravenous immunoglobulins for Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease: A systematic review with meta-analysis
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1620106
Gut microbiota and psychogenic non-epileptic seizures: i can feel it in the belly
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1684901
Approaching drug-induced parkinsonism from a neurohospitalist perspective
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1569515
Current and future clinical utilities of Parkinson’s disease and dementia biomarkers: can they help us conquer the disease?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1649141
How can an understanding of the C9orf72 gene translate into amyotrophic lateral sclerosis therapies?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1635884
Treatment of psychiatric disturbances in hypokinetic movement disorders
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1636648
Reversing the myth of phase reversals
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2020.1696193
Modification of CSF findings in multiple sclerosis in the era of rapidly expanding treatment options
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1583557
Hereditary spastic paraplegias: time for an objective case definition and a new nosology for neurogenetic disorders to facilitate biomarker/therapeutic studies
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1608824
Dasotraline in ADHD: novel or me too drug?
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1593826
Treatment options for tic disorders
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2020.1698950
Shedding light on migraine with aura: the clarifying role of advanced neuroimaging investigations
来源期刊：Expert Review of NeurotherapeuticsDOI：10.1080/14737175.2019.1638252

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

AAPS Journal封面

AAPS Journal

学科领域：医学
影响因子：3.7
中科院分区： 3区
AAPS PHARMSCITECH封面

AAPS PHARMSCITECH

学科领域：医学
影响因子：4
中科院分区： 3区
Academic Pediatrics封面

Academic Pediatrics

学科领域：医学
影响因子：2.8
中科院分区： 3区
ACTA ANAESTHESIOLOGICA SCANDINAVICA封面

ACTA ANAESTHESIOLOGICA SCANDINAVICA

学科领域：医学
影响因子：2
中科院分区： 3区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布
大类学科小类学科Top期刊综述期刊
医学3区
CLINICAL NEUROLOGY 临床神经病学
3区
PHARMACOLOGY & PHARMACY 药学
3区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
2区
CLINICAL NEUROLOGY 临床神经病学
3区
否
是
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学2区
CLINICAL NEUROLOGY 临床神经病学
2区
PHARMACOLOGY & PHARMACY 药学
2区
否
是